These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35313945)

  • 21. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.
    Morishima T; Takahashi K; Chin DWL; Wang Y; Tokunaga K; Arima Y; Matsuoka M; Suda T; Takizawa H
    Cancer Sci; 2024 Jan; 115(1):197-210. PubMed ID: 37882467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia].
    Zhao YX; Shen XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):632-6. PubMed ID: 27151043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia.
    Yun S; Vincelette ND; Yu X; Watson GW; Fernandez MR; Yang C; Hitosugi T; Cheng CH; Freischel AR; Zhang L; Li W; Hou H; Schaub FX; Vedder AR; Cen L; McGraw KL; Moon J; Murphy DJ; Ballabio A; Kaufmann SH; Berglund AE; Cleveland JL
    Blood Cancer Discov; 2021 Mar; 2(2):162-185. PubMed ID: 33860275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
    Abou Dalle I; DiNardo CD
    Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
    Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
    J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
    Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
    Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
    Liu X; Gong Y
    Biomark Res; 2019; 7():22. PubMed ID: 31660152
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Babakhanlou R; DiNardo C; Borthakur G
    Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Fiehn O; Showalter MR; Schaner-Tooley CE; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26943899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
    Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
    Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
    Ogawara Y; Kitabayashi I
    Rinsho Ketsueki; 2015 Aug; 56(8):1045-52. PubMed ID: 26345565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
    Zhang GF; Jensen MV; Gray SM; El K; Wang Y; Lu D; Becker TC; Campbell JE; Newgard CB
    Cell Metab; 2021 Apr; 33(4):804-817.e5. PubMed ID: 33321098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
    Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
    Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
    Lachowiez C; DiNardo CD; Stein E
    Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
    Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.